Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06295588 · ClinicalTrials.gov registry record · Phase 2
Clinical Trial of the Seaweed Supplement Fucoidan in Survivors of Cancer
A Phase 2 study of Inflammation and Fatigue, sponsored by University of Rochester.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06295588: Recruiting Phase 2 study of Inflammation and Fatigue, sponsored by University of Rochester.
NCT06295588 is a Phase 2 study of Inflammation and Fatigue that is actively recruiting participants, run by University of Rochester. The registered enrollment target is 40 participants, below the 288-participant average among 132 other Inflammation trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06295588, a Phase 2 study of Inflammation and Fatigue, is actively recruiting participants, sponsored by University of Rochester.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine the feasibility of an 8-week fucoidan supplement intervention for patients with fatigue post-cancer treatment and assess changes in fatigue, frailty, and inflammation.
Conditions Studied
Interventions
- DRUG Fucoidan extracted from F. Vesiculosus
- DRUG Fucoidan extracted from U. Pinnatifida
Study Locations (1)
New York
- University of Rochester Medical Center - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-07-26 |
| Est. Completion | 2027-06-01 |
| Phase | Phase 2 |
What NCT06295588 shows while recruiting
NCT06295588 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 288-participant average among 132 other Inflammation trials with a reported enrollment target (86% lower).
The record links to 2 conditions, with Inflammation appearing as the primary indexed condition, and to 2 interventions - of which Fucoidan extracted from F. Vesiculosus is the first listed.
NCT06295588 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06295588 about?
NCT06295588 is a clinical study titled "Clinical Trial of the Seaweed Supplement Fucoidan in Survivors of Cancer". To determine the feasibility of an 8-week fucoidan supplement intervention for patients with fatigue post-cancer treatment and assess changes in fatigue, frailty, and inflammation.
What is the current status of trial NCT06295588?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2025-07-26. Estimated completion is 2027-06-01.
What conditions does trial NCT06295588 study?
This clinical trial studies the following conditions: Inflammation, Fatigue.
What interventions are being tested in trial NCT06295588?
The interventions under investigation include: Fucoidan extracted from F. Vesiculosus (DRUG), Fucoidan extracted from U. Pinnatifida (DRUG).
Who is sponsoring clinical trial NCT06295588?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06295588 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Inflammation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06295588's enrollment target sits among peer trials
40 83rd of 132 higher than 46 of 132 other Inflammation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Inflammation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reducing Frailty for Older Cancer Survivors Using Supplements II
RECRUITING · Phase 2
-
Focused Orticumab Research for Treating Inflammation in Coronary Arteries
RECRUITING · Phase 2
-
Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab
RECRUITING · Phase 2
-
Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1
RECRUITING · Phase 2
-
Modulating Exercise Dosage to Improve Concussion Recovery
RECRUITING · Phase 2
-
Passive Stretching in Peripheral Arterial Disease Patients
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI